A pH-sensitive cell-penetrating peptide (HNLS-3) with nuclear localization capacity delivered camptothecin into cancer cell nuclei with enhanced cytotoxicity and selectivity versus the free drug.
pH-activated + nuclear-targetedHNLS-3 activates in acidic tumors, escapes endosomes, and delivers drug cargo directly to the cancer cell nucleus — triple-targeting in one peptide
What the researchers found
HNLS-3 displayed pH-dependent cellular uptake, endosomal escape, and nuclear localization. HNLS-3-CPT conjugate showed enhanced cytotoxicity and selectivity compared to free CPT.
Why it matters
Many cancer drugs work in the nucleus but can't get there efficiently. A peptide that activates in acidic tumors AND delivers drugs to the nucleus solves two delivery problems simultaneously.
The numbers in context
6 His residues; PFVYLI sequence; NLS; enhanced CPT cytotoxicity; improved selectivity; pH-dependent activation
How the study worked
Peptide design combining 6 histidine residues, hydrophobic sequence PFVYLI, and nuclear localization sequence. pH-dependent uptake, endosomal escape, and nuclear localization assessed. Cytotoxicity of peptide-drug conjugate versus free drug measured.
Who was studied
Cancer cell lines (in vitro)
What this study cannot tell us
In vitro cancer cell study only. No animal tumor models tested. Peptide stability in blood and biodistribution unknown. Manufacturing complexity of peptide-drug conjugates.
How to read the evidence
Low evidence grade: in vitro proof-of-concept with no animal data.
When this study was published
Published 2021. Stimulus-responsive CPPs continue to advance for targeted cancer therapy.
The bigger picture
Smart peptide delivery systems that respond to tumor-specific conditions (like acidity) and target specific subcellular compartments (like the nucleus) represent the next frontier in precision drug delivery.
Questions still open
- Would HNLS-3 deliver camptothecin effectively in vivo tumor models?
- Can this dual-targeting approach (tumor pH + nucleus) be applied to other nuclear-acting drugs?
- How does the peptide-drug conjugate stability compare in blood versus tumor tissue?
Common questions
Why target the cell nucleus with cancer drugs?
How does the peptide know to activate in tumors?
Read the original research
Design of acid-activated cell-penetrating peptides with nuclear localization capacity for anticancer drug delivery.
Journal of peptide science : an official publication of the European Peptide Society, 27(10), e3354
Citation
Huang, Sujie; Zhu, Zhongwen; Jia, Bo; Zhang, Wei; Song, Jingjing. (2021). Design of acid-activated cell-penetrating peptides with nuclear localization capacity for anticancer drug delivery.. Journal of peptide science : an official publication of the European Peptide Society, 27(10), e3354. https://doi.org/10.1002/psc.3354